High-dose cytosine arabinoside plus etoposide as initial treatment for acute myeloid leukaemia: a single centre study

In a single centre, 52 newly diagnosed patients with acute myeloid leukemia (AML) under the age of 56 years received induction chemotherapy commencing with high-dose cytosine arabinoside (Ara-C) and etoposide (Protocol BF11), followed by Ara-C, 6 thioguanine (6TG). A total of 67% of patients entered...

Full description

Saved in:
Bibliographic Details
Published inBritish journal of cancer Vol. 62; no. 5; pp. 830 - 833
Main Authors PARIKH, P, POWLES, R, ABOUD, H, CAVENAGH, J, ROWLEY, M, MCELWAIN, T, HEWETSON, M, TRELEAVEN, J, HELENGLASS, G, GORE, M, ROSE, M, TALBOT, D, MILAN, S, SMITH, C, PINKERTON, R
Format Journal Article
LanguageEnglish
Published Basingstoke Nature Publishing Group 01.11.1990
Subjects
Adolescent
Adult
Antineoplastic agents
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biological and medical sciences
Chemotherapy
Child
Cytarabine - administration & dosage
Cytarabine - therapeutic use
Etoposide - administration & dosage
Etoposide - therapeutic use
Female
Humans
Leukemia, Myeloid, Acute - drug therapy
Male
Medical sciences
Middle Aged
Pharmacology. Drug treatments
Antineoplastic agent
Human
Chemotherapy
Polychemotherapy
Malignant hemopathy
High dose
Induction treatment
Acute myelocytic leukemia
Online AccessGet full text

Cover

More Information
Summary:In a single centre, 52 newly diagnosed patients with acute myeloid leukemia (AML) under the age of 56 years received induction chemotherapy commencing with high-dose cytosine arabinoside (Ara-C) and etoposide (Protocol BF11), followed by Ara-C, 6 thioguanine (6TG). A total of 67% of patients entered remission using these drugs. An anthracycline was added for those patients not in remission. The overall remission rate (CR) was 86.5% (45/52), with a minimum follow-up of 90 days. Patients are hospitalised for relatively short periods, and consequently require less blood product and antibiotic support. Patients in continuing first remission following induction with Ara-C and etoposide are similar in number to those in continuing first remission who initially received an anthracycline. This would imply that the efficiency of Ara-C and etoposide in inducing long-term disease-term survival is comparable with anthracycline-containing regimens. We conclude that high-dose Ara-C and etoposide used in the first induction cycle for treating AML have good antileukaemic effect with acceptable toxicity.
ISSN:0007-0920
1532-1827
DOI:10.1038/bjc.1990.387